Advice

Following a re-submission

betaine anhydrous (Cystadane) is not recommended for use within NHS Scotland as adjunctive treatment of homocystinuria involving deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylene-tetrahydrofolate reductase (MTHFR) or cobalamin cofactor metabolism (cbl).

Clinical efficacy data for betaine anhydrous are limited.

The manufacturer did not present a sufficiently robust economic evaluation to gain acceptance by SMC.

Download detailed advice79KB (PDF)

Download

Medicine details

Medicine name:
betaine anhydrous oral powder (Cystadane)
SMC ID:
407/07
Indication:
Adjunctive treatment of homocystinuria
Pharmaceutical company
Orphan Europe (UK) Ltd
BNF chapter
Nutrition and blood
Submission type
Resubmission
Status
Not recommended
Date advice published
09 March 2009